Business
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application
About this update from Envveno Medical Corporation
[{"type":"text","content":"Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) (\"enVVeno\" or the \"Company\"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien, and ev3. \"Andrew's experience in formulating and executing strategies for new product launches will be invaluable as we begin to plan for the commercialization of the VenoValve,\" said Robert Berman, enVVeno Medical's Chief Executive Officer. \"I look forward to working closely with Andrew on our U.S. product launch strategy for the VenoValve and in recruiting a world-class sales and marketing team to execute that strategy.\"\"I have been involved with several innovative products throughout my career and would put the VenoValve at the top of the list in terms of its potential to fulfill the unmet medical need for the millions of patients that suffer from severe, deep venous Chronic Venous Insufficiency (CVI),\" added Mr. Cormack. \"I am excited to work on the VenoValve commercialization strategy and to lead the commercial team to ensure that the VenoValve reaches its full potential.\" Mr. Cormack has held numerous regional, national, and international sales and marketing positions throughout his almost 25-year career in med-tech and holds a Bachelor of Arts degree in Kinesiology from The University of Western Ontario, where he graduated with honors.enVVeno is advancing the VenoValve, a first-in-class, surgical replacement venous valve for patients suffering from severe CVI caused by incompetent valves in the deep venous system. CVI is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypert...